본문 바로가기
KERD
논문KCI 등재

Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment

Soo-Jeung Park|Young S. Hahn
대한간학회 (The korean Association for the Study of the Liver)|2023.02|Clinical and Molecular Hepatology|제29권 제1호|pp. 65-76

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

ImmunityHepatocellular carcinomaExosomesHepatitis CCell communication

초록

Hepatitis C virus (HCV) infection is remarkably efficient in establishing viral persistence, leading to the development of liver cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antiviral agents (DAAs) are promising HCV therapies to clear the virus. However, recent reports indicate potential increased risk of HCC development among HCV patients with cirrhosis following DAA therapy. CD8+ T-cells participate in controlling HCV infection. However, in chronic hepatitis C patients, severe CD4+ and CD8+ T-cell dysfunctions have been observed. This suggests that HCV may employ mechanisms to counteract or suppress the host T-cell responses. The primary site of viral replication is within hepatocytes where infection can trigger the expression of costimulatory molecules and the secretion of immunoregulatory cytokines. Numerous studies indicate that HCV infection in hepatocytes impairs antiviral host immunity by modulating the expression of immunoregulatory molecules. Hepatocytes expressing whole HCV proteins upregulate the ligands of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and transforming growth factor β (TGF-β) synthesis compared to those in hepatocytes in the absence of the HCV genome. Importantly, HCV-infected hepatocytes are capable of inducing regulatory CD4+ T-cells, releasing exosomes displaying TGF-β on exosome surfaces, and generating follicular regulatory T-cells. Recent studies report that the expression profile of exosome microRNAs provides biomarkers of HCV infection and HCV-related chronic liver diseases. A better understanding of the immunoregulatory mechanisms and identification of biomarkers associated with HCV infection will provide insight into designing vaccine against HCV to bypass HCV-induced immune dysregulation and prevent development of HCV-associated chronic liver diseases.

Abstract

Hepatitis C virus (HCV) infection is remarkably efficient in establishing viral persistence, leading to the development of liver cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antiviral agents (DAAs) are promising HCV therapies to clear the virus. However, recent reports indicate potential increased risk of HCC development among HCV patients with cirrhosis following DAA therapy. CD8+ T-cells participate in controlling HCV infection. However, in chronic hepatitis C patients, severe CD4+ and CD8+ T-cell dysfunctions have been observed. This suggests that HCV may employ mechanisms to counteract or suppress the host T-cell responses. The primary site of viral replication is within hepatocytes where infection can trigger the expression of costimulatory molecules and the secretion of immunoregulatory cytokines. Numerous studies indicate that HCV infection in hepatocytes impairs antiviral host immunity by modulating the expression of immunoregulatory molecules. Hepatocytes expressing whole HCV proteins upregulate the ligands of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and transforming growth factor β (TGF-β) synthesis compared to those in hepatocytes in the absence of the HCV genome. Importantly, HCV-infected hepatocytes are capable of inducing regulatory CD4+ T-cells, releasing exosomes displaying TGF-β on exosome surfaces, and generating follicular regulatory T-cells. Recent studies report that the expression profile of exosome microRNAs provides biomarkers of HCV infection and HCV-related chronic liver diseases. A better understanding of the immunoregulatory mechanisms and identification of biomarkers associated with HCV infection will provide insight into designing vaccine against HCV to bypass HCV-induced immune dysregulation and prevent development of HCV-associated chronic liver diseases.

참고문헌 (82)

  1. Alter HJ, "Hepatitis C in asymptomatic blood donors", Hepatology, 26(3 Suppl 1), pp.29S~33S (1997)
  2. Hoofnagle JH, "Hepatitis C : the clinical spectrum of disease", Hepatology, 26(3 Suppl 1), pp.15S~20S (1997)
  3. Nagata H, "Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C", J Hepatol, 67, pp.933~939 (2017)
  4. Kanwal F, "Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents", Gastroenterology, 153, pp.996~1005 (2017)
  5. Bowen DG, "Adaptive immune responses in acute and chronic hepatitis C virus infection", Nature, 436, pp.946~952 (2005)
  6. Cabrera R, "An immunomodulatory role for CD4(+)CD25(+)regulatory T lymphocytes in hepatitis C virus infection", Hepatology, 40, pp.1062~1071 (2004)
  7. Boettler T, "T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection", J Virol, 79, pp.7860~7867 (2005)
  8. Burton JR Jr, "Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy", J Hepatol, 49, pp.329~338 (2008)
  9. Chen M, "Limited humoral immunity in hepatitis C virus infection", Gastroenterology, 116, pp.135~143 (1999)
  10. Cerny A, "Pathogenesis of chronic hepatitis C : immunological features of hepatic injury and viral persistence", Hepatology, 30, pp.595~601 (1999)
  11. Rosen HR, "Hepatitis C pathogenesis : mechanisms of viral clearance and liver injury", Liver Transpl, 9, pp.S35~S43 (2003)
  12. MacDonald AJ, "CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons", J Infect Dis, 185, pp.720~727 (2002)
  13. Sugimoto K, "Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response", Hepatology, 37, pp.590~599 (2003)
  14. Marie JC, "TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+regulatory T cells", J Exp Med, 201, pp.1061~1067 (2005)
  15. Murai M, "Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis", Nat Immunol, 10, pp.1178~1184 (2009)
  16. Kimura T, "Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus", J Infect Dis, 193, pp.1371~1374 (2006)
  17. Grakoui A, "Expression and identification of hepatitis C virus polyprotein cleavage products", J Virol, 67, pp.1385~1395 (1993)
  18. Barth H, "Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction", J Virol, 80, pp.10579~10590 (2006)
  19. Crovatto M, "Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus", Haematologica, 85, pp.356~361 (2000)
  20. Roehlen N, "Liver fibrosis : mechanistic concepts and therapeutic perspectives", Cells, 9, pp.875~ (2020)
  21. Correia MP, "Hepatocytes and IL-15 : a favorable microenvironment for T cell survival and CD8+ T cell differentiation", J Immunol, 182, pp.6149~6159 (2009)
  22. Sun J, "Parenchymal expression of CD86", B7. 2 contributes to hepatitis C virus-related liver injury, 2005, pp.79, 10730~10739
  23. Chen W, "HCV genomic RNA activates the NLRP3 inflammasome in human myeloid cells", PLoS One, 9, pp.e84953~ (2014)
  24. Appay V, "RANTES : a versatile and controversial chemokine", Trends Immunol, 22, pp.83~87 (2001)
  25. Golden-Mason L, "Loss of IL-7 receptor alpha-chain(CD127)expression in acute HCV infection associated with viral persistence", Hepatology, 44, pp.1098~1109 (2006)
  26. Blight KJ, "Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication", J Virol, 76, pp.13001~13014 (2002)
  27. Wakita T, "Production of infectious hepatitis C virus in tissue culture from a cloned viral genome", Nat Med, 11, pp.791~796 (2005)
  28. Latchman Y, "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", Nat Immunol, 2, pp.261~268 (2001)
  29. Barber DL, "Restoring function in exhausted CD8 T cells during chronic viral infection", Nature, 439, pp.682~687 (2006)
  30. Wherry EJ, "Molecular signature of CD8+ T cell exhaustion during chronic viral infection", Immunity, 27, pp.670~684 (2007)
  31. Sharpe AH, "The B7-CD28 superfamily", Nat Rev Immunol, 2, pp.116~126 (2002)
  32. Gehring AJ, "The level of viral antigen presented by hepatocytes influences CD8 T-cell function", J Virol, 81, pp.2940~2949 (2007)
  33. Golden-Mason L, "Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction", J Virol, 81, pp.9249~9258 (2007)
  34. Nakamoto N, "Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization", Gastroenterology, 134, pp.1927~1937 (2008)
  35. Missale G, "Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cellmediated immune response", J Clin Invest, 98, pp.706~714 (1996)
  36. Erickson AL, "The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes", Immunity, 15, pp.883~895 (2001)
  37. Tester I, "Immune evasion versus recovery after acute hepatitis C virus infection from a shared source", J Exp Med, 201, pp.1725~1731 (2005)
  38. Urbani S, "PD-1 expression in acute hepatitis C virus(HCV)infection is associated with HCV-specific CD8 exhaustion", J Virol, 80, pp.11398~11403 (2006)
  39. Nakamoto N, "Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1", CTLA-4 blockade, 2009, pp.5, e1000313~
  40. Perrella A, "Elevated CD4+", CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution, 2006, pp.55, 1370~1371
  41. Smyk-Pearson S, "Functional suppression by FoxP3+CD4+CD25(high)regulatory T cells during acute hepatitis C virus infection", J Infect Dis, 197, pp.46~57 (2008)
  42. Hall CH, "HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGFbeta", PLoS One, 5, pp.e12154~ (2010)
  43. Taniguchi H, "Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription", J Med Virol, 72, pp.52~59 (2004)
  44. Boudreau HE, "Hepatitis C virus(HCV)proteins induce NADPH oxidase 4expression in a transforming growth factor beta-dependent manner : a new contributor to HCV-induced oxidative stress", J Virol, 83, pp.12934~12946 (2009)
  45. Valadi H, "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells", Nat Cell Biol, 9, pp.654~659 (2007)
  46. Ibrahim SH, "Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes", Hepatology, 63, pp.731~744 (2016)
  47. Verma VK, "Alcohol stimulates macrophage activation through caspasedependent hepatocyte derived release of CD40L containing extracellular vesicles", J Hepatol, 64, pp.651~660 (2016)
  48. Saha B, "Circulating and exosomepackaged hepatitis C single-stranded RNA induce monocyte differentiation via TLR7", 8 to polarized macrophages and fibrocytes, 2017, pp.198, 1974~1984
  49. Cobb DA, "Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during hepatitis C virus infection", Hepatology, 67, pp.71~85 (2018)
  50. Devhare PB, "Exosome-mediated intercellular communication between hepatitis C virus-infected hepatocytes and hepatic stellate cells", J Virol, 91, pp.e02225-16~ (2017)
  51. Bukong TN, "Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90", PLoS Pathog, 10, pp.e1004424~ (2014)
  52. Kim OK, "The pannexin 1", purinergic receptor P2X4 pathway controls the secretion of microRNA-containing exosomes by HCV-infected hepatocytes, 2021, pp.74, 3409~3426
  53. Medvedev R, "Look who’s talking-the crosstalk between oxidative stress and autophagy supports exosomal-dependent release of HCV particles", Cell Biol Toxicol, 33, pp.211~231 (2017)
  54. Azam S, "Regulation of toll-like receptor(TLR)signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases : focus on TLR4 signaling", Front Immunol, 10, pp.1000~ (2019)
  55. Grünvogel O, "Secretion of hepatitis C virus replication intermediates reduces activation of toll-like receptor 3 in hepatocytes", Gastroenterology, 154, pp.2237~2251 (2018)
  56. Rubtsov YP, "TGFbeta signalling in control of T-cellmediated self-reactivity", Nat Rev Immunol, 7, pp.443~453 (2007)
  57. Ward SM, "Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection", J Hepatol, 47, pp.316~324 (2007)
  58. Claassen MA, "Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis", J Hepatol, 52, pp.315~321 (2010)
  59. Linterman MA, "Foxp3+ follicular regulatory T cells control the germinal center response", Nat Med, 17, pp.975~982 (2011)
  60. Chung Y, "Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions", Nat Med, 17, pp.983~988 (2011)
  61. Wang L, "Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T(TFR)cells in CHB or CHC patients", J Transl Med, 12, pp.251~ (2014)
  62. Sage PT, "T follicular regulatory cells in the regulation of B cell responses", Trends Immunol, 36, pp.410~418 (2015)
  63. Mosnier JF, "The intraportal lymphoid nodule and its environment in chronic active hepatitis C : an immunohistochemical study", Hepatology, 17, pp.366~371 (1993)
  64. Spaan M, "CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses", J Hepatol, 62, pp.303~310 (2015)
  65. Raziorrouh B, "Virus-specific CD4+ T cells have functional and phenotypic characteristics of follicular T-helper cells in patients with acute and chronic HCV infections", Gastroenterology, 150, pp.696~706 (2016)
  66. Ghosh S, "The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein", Int J Cancer, 147, pp.2934~2947 (2020)
  67. Khatun M, "Mechanisms underlying hepatitis C virusassociated hepatic Fibrosis", Cells, 8, pp.1249~ (2019)
  68. Liao TL, "Hepatitis C virus-induced exosomal microRNAs and toll-like receptor 7 polymorphism regulate B-cell activating factor", mBio, 12, pp.e0276421~ (2021)
  69. Thakuri BKC, "HCV-associated exosomes upregulate RUNXOR and RUNX1 expressions to promote MDSC expansion and suppressive functions through STAT3-miR124 Axis", Cells, 9, pp.2715~ (2020)
  70. McGowan K, "Expression profiles of exosomal microRNAs from HEV-and HCV-infected blood donors and patients : a pilot study", Viruses, 12, pp.833~ (2020)
  71. Deng L, "Syntenin regulates hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes", J Hepatol, 71, pp.52~61 (2019)
  72. Takenouchi T, "Extracellular ATP induces unconventional release of glyceraldehyde-3-phosphate dehydrogenase from microglial cells", Immunol Lett, 167, pp.116~124 (2015)
  73. Sandilos JK, "Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associated C-terminal autoinhibitory region", J Biol Chem, 287, pp.11303~11311 (2012)
  74. Woehrle T, "Pannexin-1 hemichannel-mediated ATP release together with P2X1and P2X4 receptors regulate T-cell activation at the immune synapse", Blood, 116, pp.3475~3484 (2010)
  75. Csak T, "Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells", Hepatology, 54, pp.133~144 (2011)
  76. Liao TL, "Rituximab may cause increased hepatitis C virus viremia in rheumatoid arthritis patients through declining exosomal microRNA-155", Arthritis Rheumatol, 70, pp.1209~1219 (2018)
  77. Jiao X, "Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients", J Med Virol, 89, pp.1597~1605 (2017)
  78. Bhattacharjee C, "Current therapeutics against HCV", Virusdisease, 32, pp.228~243 (2021)
  79. Lindow M, "Discovering the first microRNA-targeted drug", J Cell Biol, 199, pp.407~412 (2012)
  80. Deng L, "Syntenin regulates hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes", J Hepatol, 7, pp.52~61 (2019)
  81. 김지현, "Hepatitis C virus infection stimulates transforming growth factor-β1 expression through up-regulating miR-192", The Journal of Microbiology, 54(7), pp.520~526 (2016), 한국미생물학회[DOI]
  82. Wang L, "HCVassociated exosomes promote myeloid-derived suppressor cell expansion via inhibiting miR-124 to regulate T follicular cell differentiation and function", Cell Discov, 4, pp.51~ (2018)

관련 논문AI추천

T-Cell Dysfunction and Inhibitory Receptors in Hepatitis C Virus Infection신의철, 이진오, William I. Suh대한면역학회 · Immune Network2010 · 제10권 제4호Regulatory T Cells in Hepatitis B and C Virus Infections신의철, 정민경대한면역학회 · Immune Network2016 · 제16권 제6호The Natural Killer Cell Response to HCV InfectionGolo Ahlenstiel대한면역학회 · Immune Network2013 · 제13권 제5호Current and future strategies for the treatment of chronic hepatitis COmar Alshuwaykh, Paul Y. Kwo대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradicationChung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제3호Expression of Hepatitis B Virus X Protein in Hepatocytes Suppresses CD8+ T Cell Activity박선, 김경민, 김형진, 이미진, 진영희, 최양규대한면역학회 · Immune Network2010 · 제10권 제4호

이 간행물의 다른 논문 (46건)

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detectionLuma Melo, David Martí-Aguado, Ramón Bataller, Concepción Gómez-Medinapp. 1-15PrefaceYoon Jun Kimpp. 2-2PrefaceSeung Up Kimpp. 3-3Non-alcoholic fatty liver disease: Definition and subtypesSeul Ki Han, 김문영, 백순구pp. 5-16Management of refractory ascitesFlorence Wongpp. 16-32
원문 보기